In this report, we used a CEACAM1-specific antibody together with mass cytometry to provide global insights into the potential cellular basis for CEACAM1’s immune role in melanoma, its association with the state of treatment, and its expression relative to PD1 and PD-L1. The gene discussed is PDCD1; the disease is melanoma.